HDAC9 and cancer: Since a CDK (cyclind-dependent kinase) inhibitor also showed activity against SUR cells, the combination of HDAC inhibition with CDK inhibition appears to be promising in terms of concomitant apoptosis induction and cell cycle arrest in resistant BRAF-mutant cancers.